Table 4.
Subgroup analysis of ChAd vs BNT demographics and outcomes between de novo vs relapsed ITP.
| De novo | Relapsed | OR (95% CI) | P | |
|---|---|---|---|---|
| Demographics | ||||
| Male | 19 | 4 | 2.4 (0.66-7.8) | .33 |
| Female | 18 | 9 | ||
| ChAd | 4 | 9 | 19 (3.6-83) | <.001 |
| BNT | 33 | 4 | ||
| First dose | 33 | 9 | 3.7 (0.89-14) | .18 |
| Second dose | 4 | 4 | ||
| Time from vaccination to presentation, median, d [IQR] | 17 [10–24.5] | 4 [2–25] | (Mann–Whitney U-test) | .03 |
| Outcomes | ||||
| WHO bleeding 0–1 | 23 | 12 | 0.14 (0.012-1.0) | .08 |
| WHO bleeding ≥2 | 14 | 1 | ||
| Need for second-line therapy | 23 | 3 | 5.5 (1.4-20) | .02 |
| No need for second-line therapy | 14 | 10 | ||
| On treatment at day 90 | 14 | 2 | 1.9 (0.36-11) | .67 |
| Off treatment at day 90 | 15 | 4 |